After an expanded recall of the blood pressure medication valsartan, FDA is warning the manufacturer of the carcinogenic ingredient involved.
Formulary Watch
Latest News
All News
Advertisement
Two major drug recalls in the last week include an expanded recall of a widely used blood pressure medication as well as over-the-counter infant ibuprofen.
Find out how healthcare organizations and analysts feel about new Medicare Part D proposals and drug pricing.
Here are the top 2 novel cancer drugs cleared by the agency.
FDA approved the first biosimilar to rituximab (Rituxan, Genentech) to treat non-Hodgkin lymphoma.
FDA approved an autoinjector to treat rheumatoid arthritis and other diseases.
While some pharma makers have lowered drug prices and Express Scripts is pushing more branded manufacturers to lower list prices with its new National Preferred Flex Formulary, some manufacturers are raising drug prices.
Express Scripts’ new National Preferred Flex Formulary, which offers lower list prices on certain branded drugs, is a novel way to encourage pharma makers to lower prices.
Despite concerns about a new opioid that is reportedly 1,000 times more powerful than morphine, FDA recently approved the new painkiller.
Certain groups expressed “deep concern” over FDA allowing an OTC asthma inhaler to be sold again after it was removed from the market 7 years ago. Here’s why.
Advertisement
FDA approves the first new flu drug in 20 years. Here’s what’s different about it.
A pharma maker is voluntarily recalling several lots of a major heart medication. Here’s why.
FDA recently stopped importation and sent warning letters to numerous online sellers of illegal opioids, oncology drugs and other medicines.
Pharmacy benefit managers, cardiologists, and others praised a pharma maker for significantly reducing the price of its high cholesterol drug.
A novel treatment for patients with moderate-to-severe asthma is now on the market.
A new indication for rivaroxaban (Xarelto) has been approved by FDA.
FDA approved a new antibiotic to treat community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI).
A new study linking attention-deficit hyperactivity disorder (ADHD) drugs and Parkinson’s disease could cause prescribers to re-think prescribing the medications.
Here are the top 3 new approvals from FDA.
While Teva Pharmaceutical’s new migraine prevention drug is unique, it faces competition from another major migraine treatment.
Pharmacy and healthcare experts cautiously praised the planned development of a fast-acting, better version of naloxone (Narcan), which is used to reverse the effects of opioid overdoses.
FDA okayed a first-of-its-kind treatment for hairy cell leukemia (HCL).
FDA recently approved 2 new treatments, heightening competition in the HIV-1 drug marketplace.
FDA cleared the first and only easy-to-swallow liquid drug to treat amyotrophic lateral sclerosis (ALS).
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FDA approves first postmenopausal libido treatment, Addyi
2
What IRA drug prices will mean for PBMs, health plans and patients
3
Looking ahead: What the MHE 2025 State of the Industry survey tells us about 2026
4
Biosimilars in 2025: A year of firsts
5
